Publication at Faculty of Medicine in Hradec Králové |
2014
Abstract
Smoldering multiple myeloma (SMM) is plasma cell dyscrasia that bridges the gap between monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma. In comparison to MGUS is generally the risk of progression to symptomatic myeloma much higher.
The current standard of care is not to treat until progression to symptomatic disease occurs. SMM is divided in subgroups with different risk of progression that could be identified on various risk factors.
In future high-risk patients should be targeted for early treatment, especially ultra-high risk subgroup with risk of progression in 2 years.